臨床外科67巻1号

2012年01月発行

特集 「切除困難例」への化学療法後の手術―根治切除はどこまで可能か

切除不能大腸癌肝転移に対するconversion therapy

著者： 土居浩一¹ 別府透¹² 近本亮¹ 美馬公介¹ 岡部弘尚¹ 林洋光¹ 今井克憲¹ 新田英利¹ 坂本快郎¹² 宮本裕士¹ 渡辺雅之¹ 石河隆敏¹ 馬場秀夫¹

所属機関： ¹熊本大学大学院生命科学研究部消化器外科学 ²熊本大学附属病院消化器癌集学的治療学

ページ範囲：P.46 - P.53

文献概要

【ポイント】

◆分子標的治療薬を含めた化学療法の進歩によって切除不能大腸癌肝転移の10～40％が切除可能となり，KRAS野生型の場合には肝切除率は43％，R0切除率は38％に達するとの報告もみられる．

◆切除不能大腸癌肝転移におけるconversion therapyでは，「術前治療回数」「切除術式」「切除のタイミング」の至適条件を踏まえて治療にあたることが重要である．

参考文献

1）大腸癌研究会（編）：大腸癌治療ガイドライン．医師用　2010年版．金原出版，2010

2）Alberts SR, Horvaith WL, Sternfield WC, et al：Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer；a NorthCentral Cancer Treatment Group phase Ⅱ study. J Clin Oncol 23：9243-9249, 2005

3）Falcone A, Ricci S, Brunetti I, et al：Phase Ⅲ trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan（FOLFOXIRI）as first-line treatment for metastatic colorectal cancer；the Gruppo Oncologico Nord Ovest. J Clin Oncol 25：1670-1676, 2007

4）Coskun U, Buyukberber S, Yaman E, et al：Xelox（capecitabine plus oxaliplutin）as neoadjuvant chemotherapy of unrespectable liver metastases in colorectal cancer patients. Neoplasm 55：65-70, 2008

5）Skof E, Rebersek M, Hlebanja Z：Capecitabine plus irinotecan（XELIRI regimen）compared to 5-FU/LV plus irinotecan（FOLFIRI regimen）as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer：a randomized prospective phase Ⅱ trial. BMC Cancer 22：120-128, 2009

6）Min BS, Kim NK, Ahn JB, et al：Cetuximab in combination with 5-fluorouracil, leucovorin and irinotrecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Onkologie 30：637-643, 2007

7）Van Cutsem E, Rivera F, Berry S, et al：Safety and efficacy of first line bevacizmab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer：BEAT study. Ann Oncol 20：1842-1847, 2009

8）Folprecht G, Gruenberger T, Bechstein WO, et al：Tumor response and secondary respectability of colorectal liver metastases following neoadjuvant chemotherapy with cetximab；the CELIM randomized phase 2 trial. Lancet Oncol 11：38-47, 2010

9）de Gramont A, Figer A, Seymour M, et al：Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18：2938-2947, 2004

10）Douillard JY, Cunningham D, Navarro M, et al：Irinotecan cmbined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. Lancet 355：1041-1047, 2000

11）Adam R, Delvart V, Pascal G, et al：Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy.：A model to predict long-term survival. Ann Surg 240：644-657, 2004

12）Folprecht G, Grothey A, Albert S, et al：Neoadjuvant treatment of unresectable colorectal liver metastases：correlation between tumor response and resection rated. Ann Oncol 16：1311-1319, 2005

13）Adam R, Pascal G, Castaining D, et al：Tumor progression while on chemotherapy；a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240：1052-1064, 2004

14）Aloia T, Sebagh M, Passe M, et al：Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxalipatin in colorectal liver metastases. J Clin Oncol 24：4983-4990, 2006

15）Nakano H, Oussoultzogou E, Rosso E, et al：Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247：118-124, 2008

16）Chun YS, Laurent A, Maru D：Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 10：278-286, 2009

17）Vauthey JN, Pawlik TM, Ribero D, et al：Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24：2065-2072, 2006

18）Saltz LB, Clarke S, Diaz-Rubio E, et al：Bevacizumab in combination with oxaliplatin-based chemotherapy as first line therapy in metastatic colorectal cancer：a randomized phase Ⅲ study. J Clin Oncol 26：2013-2019, 2008

19）Van Cutsem E, Nowacki M, Lang I, et al：Randomised phase Ⅲ study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with colorectal cancer：the CRYSTAL trial. ASCO abstract No. 4000, 2007

20）Piessevaux H, Schlichting M, Heeger S, et al：Early tumor shrinkage for prediction of efficacy of cetuximab in metastatic colorectal cancer（mCRC）：analysis from the CRYSTAL study. ESMO abstract No. 596P, 2010

21）Piessevaux H, Bokemeyer C, Schlichting M, et al：Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer（mCRC）treated with FOLFOX4 with or without cetuximab：leson from the OPUS trial. ASCO-GI abstract No. 398, 2011

22）Maugan TS, Adams RA, Smith CG, et al：Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer：results of the randomized phse 3 MRC COIN trial. Lancet 377：2103-2114, 2011

23）Nalluri SR, Chu D, Keresztes R, et al：Risk of venous thromboembolism with angiogenesis inhibitor bevacizmab in cancer patients：a meta-analysis. JAMA 300：2277-2285, 2008

24）Klinger M, Eipeldauer S, Hacker S, et al：Bevacizmab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35：515-520, 2009

25）Ribero D, Wang H, Donadon M, et al：Bevacizmab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110：2761-2767, 2007

26）Cunningham D, Humblet Y, Siena S, et al：Cetximab monotherapy and cetximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351：337-345, 2004

27）Jonker DJ, O’Callaghan CJ, Karapetis CS,et al：Cetuximab for the treatment of colorectal cancer. N Engl J Med 357：2040-2048, 2007

28）Elias D, Sideris L, Pocard M, et al：Results of R0 resection for colorectal liver metastses associated with extra hepatic disease Ann Surg Oncol 11：274-280, 2003

29）Adam R, de Haas RJ, Wicherts DA, et al：Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol 26：3672-3680, 2008

30）Oussoultzoglou E, Romain B, Panaro F, et al：Long-term survival after liver resection for colorectal liver metastases in patients with hepatic pedic lymph nodes involvement in the era of new chemotrherapy regimens. Ann Surg 249：879-886, 2009

31）Kokudo N, Tada K, Seki M, et al：Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg 181：153-159, 2001

32）Ekberg H, Tranberg KG, Andersson R, et al：Determinants of survival in liver resection for colorectal secondaries. Br J Surg 73：727-731, 1986

33）Yamamoto J, Shimada K, Kosuge T, et al：Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 86：332-337, 1999

34）Kokudo N, Imamura H, Sugawara Y, et al：Surgery for multiple hepatic colorectal metastases. J Hepatobiliary Pancreat Surg 11：84-91, 2004

35）Abdala Ek, Vauthey JN, Ellis LM, et al：Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239：818-827, 2004

36）Adam R, Whicherts DA, de Haas RJ, et al：Complete pathologic response after preoperative chemotherapy for colorectal liver metastases：myth or reality? J Clin Oncol 26：1635-1641, 2008

37）Daniel GH：Safety of oxaliplatin in the treatment of colorectal cancer. Oncol 11：15-20, 2000

38）Masi G, Loupakis F, Pollina L, et al：Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan（FOLFOXIRI）followed by radical surgery of metastases. Ann Surg 249：420-425, 2009

39）Zovarino D, Kishi Y, Maru M, et al：Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal liver metastases. ASCO-GI #295, 2009

40）Beppu T, Sakamoto Y, Hasegawa K, et al：A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection：multicenter data collection as a Project Study for Hepatic Surgery of Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 11：2011 Oct 22,［Epub ahead of print］

41）Beppu T, Hayashi N, Masuda T, et al：FOLFOX enables high respectability and excellent prognosis for initially unresectable colorectal liver metastases. Anticancer Res 30：1015-1020, 2010

42）Komori H, Beppu T, Baba Y, et al：Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japaneses patients. Int J Clin Oncol 15：263-270, 2010